Indian portion of GSK-Novartis swap approved by GSK board

The board of directors at GlaxoSmithKline ($GSK) voted to approve the last phase of a three-part deal with Novartis ($NVS), transferring GSK's cancer drug portfolio to Novartis Healthcare Pvt, its Indian arm. Distribution rights were ceded in exchange for acquiring the Swiss-based company's vaccines portfolio.

In a financial filing, GSK said it expected the deal with Novartis to be profit-neutral, but it also reported that its stock fell 61.24 percent during the last quarter of 2014 as various aspects of the transaction were taking place. GSK blamed "supply constraints."

The arrangement, which remains subject to approval by regulatory and other authorities, was reached nearly a year ago when the two agreed to swap vaccines for cancer drugs and related research-and-development activities.

- see more at NDTV/Press Trust of India

Related Stories:
$16B deal for GlaxoSmithKline oncology meds turns Novartis into cancer heavyweight
GSK plc announces major three-part transaction with Novartis to drive sustainable sales growth, improve long-term earnings and deliver increasing returns to shareholders

Suggested Articles

As AZ and FibroGen have yet to submit the novel anemia drug to the U.S. regulators, national reimbursement talks are already underway in China.

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.